ArticleRSC medicinal chemistry2024
Design, synthesis, and antiproliferative evaluation of novel dehydroabietic acid-1,2,3-triazole-oxazolidinone hybrids.
Yaju Wu, Lin Huang, Xianli Ma, Xiaoqun Zhou, Qian Li, Fangyao Li
Abstract read
In one paragraphArticle in RSC medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
6 authors.
Yaju WuGuangxi Key Laboratory of Drug Discovery and Optimization, Guangxi Engineering Research Center for Pharmaceutical Molecular Screening and Druggability Evaluation, School of Pharmacy, Guilin Medical University Guilin 541199 PR China lifangyao2006@163.com +86 773 229 5179.
Lin HuangGuangxi Key Laboratory of Drug Discovery and Optimization, Guangxi Engineering Research Center for Pharmaceutical Molecular Screening and Druggability Evaluation, School of Pharmacy, Guilin Medical University Guilin 541199 PR China lifangyao2006@163.com +86 773 229 5179.
Xianli MaGuangxi Key Laboratory of Drug Discovery and Optimization, Guangxi Engineering Research Center for Pharmaceutical Molecular Screening and Druggability Evaluation, School of Pharmacy, Guilin Medical University Guilin 541199 PR China lifangyao2006@163.com +86 773 229 5179.
Xiaoqun ZhouGuangxi Key Laboratory of Drug Discovery and Optimization, Guangxi Engineering Research Center for Pharmaceutical Molecular Screening and Druggability Evaluation, School of Pharmacy, Guilin Medical University Guilin 541199 PR China lifangyao2006@163.com +86 773 229 5179.
Qian LiGuangxi Key Laboratory of Drug Discovery and Optimization, Guangxi Engineering Research Center for Pharmaceutical Molecular Screening and Druggability Evaluation, School of Pharmacy, Guilin Medical University Guilin 541199 PR China lifangyao2006@163.com +86 773 229 5179.
Fangyao LiGuangxi Key Laboratory of Drug Discovery and Optimization, Guangxi Engineering Research Center for Pharmaceutical Molecular Screening and Druggability Evaluation, School of Pharmacy, Guilin Medical University Guilin 541199 PR China lifangyao2006@163.com +86 773 229 5179.ORCID https://orcid.org/0000-0003-2278-4531 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
A series of novel dehydroabietic acid derivatives containing both 1,2,3-triazole and oxazolidinone 4a-4t have been synthesized and their antiproliferative activity
Identifiers
PMID38389893
PMCPMC10880940
What OpenQuestion holds
Textmetadata
Read underepoch 390